Page 13 - Read Online

Aziz et al. Cancer Drug Resist 2020;3:113-6 I http://dx.doi.org/10.20517/cdr.2020.06 Page 115

Although methylation and acetylation are classical epigenetic events, regulation through miRNAs is also
considered an example of epigenetic modification. Further, because of the importance of miRNAs in the
regulation of several physiological processes, their expression is itself tightly controlled, often through
epigenetic regulation [20-22] , thus making miRNAs an important part of cellular epigenetic machinery. The
[23]
article by Biersack touches upon the role of miRNAs in resistance to alkylating anticancer agents, with a
focus on both natural and synthetic alkylating agents and their interactions with miRNAs.

In summary, this Special Issue on the epigenetic basis of cancer drug resistance touches upon some very
diverse and hot topics that detail the current progress in understanding the importance of epigenetic events
in determining the resistance against various therapies and in a number of different cancers. Without such
understanding, the design of novel therapies to counter drug resistance will be impossible.

DECLARATIONS
Authors’ contributions
Drafted and proof-read the article: Aziz MH, Ahmad A

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Peters GJ. Cancer drug resistance: a new perspective. Cancer Drug Resist 2018;1:1-5.
2. Ahmad A. Editorial: cancer epigenetics. Curr Cancer Drug Targets 2018;18:3-4.
3. Ahmad A. Cancer epigenetics: clinical perspectives. Curr Cancer Drug Targets 2019;19:513-4.
4. Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, et al. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard
therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 2013;6:77.
5. Lu Y, Liu Y, Oeck S, Glazer PM. Hypoxia promotes resistance to EGFR inhibition in NSCLC Cells via the histone demethylases,
LSD1 and PLU-1. Mol Cancer Res 2018;16:1458-69.
6. Yue J, Lv D, Wang C, Li L, Zhao Q, et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in
EGFR-mutant NSCLC by targeting integrin beta3. Oncogene 2018;37:4300-12.
7. White JC, Pucci P, Crea F. The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors. Cancer
Drug Resist 2019;2:326-34.
8. Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, et al. Epigenetic therapy for ovarian cancer: promise and progress.
Clin Epigenetics 2019;11:7.
9. Schwarzenbach H, Gahan PB. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. Cancer
Drug Resist 2019;2:271-96.
10. Ahmad A. Epigenetics in personalized management of lung cancer. Adv Exp Med Biol 2016;890:111-22.